Last reviewed · How we verify

Gadobutrol (Gadovist/Gadavist)

Insel Gruppe AG, University Hospital Bern · FDA-approved active Small molecule

Gadobutrol (Gadovist/Gadavist) is a Gadolinium-based contrast agent (GBCA) Small molecule drug developed by Insel Gruppe AG, University Hospital Bern. It is currently FDA-approved for MRI contrast enhancement for brain imaging, MRI contrast enhancement for body imaging including liver, kidney, and other organs, MRI angiography.

Gadobutrol is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues.

Gadobutrol is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues. Used for MRI contrast enhancement for brain imaging, MRI contrast enhancement for body imaging including liver, kidney, and other organs, MRI angiography.

At a glance

Generic nameGadobutrol (Gadovist/Gadavist)
SponsorInsel Gruppe AG, University Hospital Bern
Drug classGadolinium-based contrast agent (GBCA)
TargetWater proton relaxation (T1 relaxation enhancement)
ModalitySmall molecule
Therapeutic areaDiagnostic Imaging
PhaseFDA-approved

Mechanism of action

Gadobutrol is a macrocyclic gadolinium chelate complex that distributes in the extracellular space and increases signal intensity on T1-weighted MRI images. The paramagnetic gadolinium ion accelerates the relaxation of nearby water protons, creating enhanced contrast that allows better visualization of tissue perfusion, vascularity, and pathological lesions during MRI examinations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Gadobutrol (Gadovist/Gadavist)

What is Gadobutrol (Gadovist/Gadavist)?

Gadobutrol (Gadovist/Gadavist) is a Gadolinium-based contrast agent (GBCA) drug developed by Insel Gruppe AG, University Hospital Bern, indicated for MRI contrast enhancement for brain imaging, MRI contrast enhancement for body imaging including liver, kidney, and other organs, MRI angiography.

How does Gadobutrol (Gadovist/Gadavist) work?

Gadobutrol is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues.

What is Gadobutrol (Gadovist/Gadavist) used for?

Gadobutrol (Gadovist/Gadavist) is indicated for MRI contrast enhancement for brain imaging, MRI contrast enhancement for body imaging including liver, kidney, and other organs, MRI angiography.

Who makes Gadobutrol (Gadovist/Gadavist)?

Gadobutrol (Gadovist/Gadavist) is developed and marketed by Insel Gruppe AG, University Hospital Bern (see full Insel Gruppe AG, University Hospital Bern pipeline at /company/insel-gruppe-ag-university-hospital-bern).

What drug class is Gadobutrol (Gadovist/Gadavist) in?

Gadobutrol (Gadovist/Gadavist) belongs to the Gadolinium-based contrast agent (GBCA) class. See all Gadolinium-based contrast agent (GBCA) drugs at /class/gadolinium-based-contrast-agent-gbca.

What development phase is Gadobutrol (Gadovist/Gadavist) in?

Gadobutrol (Gadovist/Gadavist) is FDA-approved (marketed).

What are the side effects of Gadobutrol (Gadovist/Gadavist)?

Common side effects of Gadobutrol (Gadovist/Gadavist) include Headache, Dizziness, Nausea, Injection site reactions, Gadolinium retention (systemic).

What does Gadobutrol (Gadovist/Gadavist) target?

Gadobutrol (Gadovist/Gadavist) targets Water proton relaxation (T1 relaxation enhancement) and is a Gadolinium-based contrast agent (GBCA).

Related